PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $56.7 million in its third quarter.

The Palo Alto, California-based company said it had a loss of 42 cents per share.

The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 60 cents per share.

The rare disease drug developer posted revenue of $353.2 million in the period, also beating Street forecasts. Six analysts surveyed by Zacks expected $296.6 million.

BridgeBio Pharma shares have declined 7.5% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $70.78, a climb of 6% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BBIO at https://www.zacks.com/ap/BBIO